Benzi L, Sabino F, Ciccarone A M, Cecchetti P, Di Cianni G, Cicchetti V, Navalesi R
Chair of Metabolic Disease, University of Pisa, Italy.
Cardiology. 1990;77 Suppl 5:63-6. doi: 10.1159/000174698.
Diabetes mellitus was assessed by investigating 8 type I diabetic patients, in good metabolic control and with congestive heart failure, who were studied after 3 weeks of placebo and ibopamine (100 mg t.i.d.) treatment. Metabolic control and daily insulin dose did not change in any patient during the study. The insulin-mediated glucose uptake during the clamp studies showed no variation after placebo or ibopamine therapy. Total cholesterol, HDL-cholesterol and triglycerides concentrations remained unchanged. This study clearly suggests that ibopamine administered at a daily dose of 300 mg for 3 weeks presents a metabolic safety in type I diabetic patients.
通过对8名I型糖尿病患者进行研究来评估糖尿病情况，这些患者代谢控制良好且患有充血性心力衰竭，在接受3周安慰剂和异波帕胺（100毫克，每日三次）治疗后进行研究。在研究期间，任何患者的代谢控制和每日胰岛素剂量均未改变。钳夹研究期间胰岛素介导的葡萄糖摄取在安慰剂或异波帕胺治疗后无变化。总胆固醇、高密度脂蛋白胆固醇和甘油三酯浓度保持不变。这项研究清楚地表明，每日剂量300毫克的异波帕胺给药3周对I型糖尿病患者具有代谢安全性。
